Keytruda can be a brand (trade) name for pembrolizumab. It is given by intravenous infusion every three to six weeks. Almost never, the use of Keytruda results within the immune system attacking healthier tissues which can cause serious side effects like pneumonitis, colitis, or hepatitis. In many people, the use of Keytruda has resulted within the… Read More